Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Nanjing's NJCTTQ Signs $4 Billion In-Licensing Deal for Bi-Specific Immunotherapies from Abpro

publication date: Feb 28, 2019

NJCTTQ, a Nanjing pharma, announced a deal worth up to $4 billion to co-develop bispecific immunotherapies discovered by Abpro of Massachusetts. NJCTTQ will have China and Thai rights to multiple immunotherapies discovered by Abpro’s DiversImmune™ antibody discovery platform for T-cell engagement. NJCTTQ will make a $60 million near-term payment to Abpro to underwrite R&D expenses and be responsible for the remainder in milestones and royalties. NJCTTQ is a subsidiary of CTTQ Pharma, a division of Sino Biopharm. More details....

Stock Symbol: (HK: 1170)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.